Dr. Sebastien Foulquier, Pharm.D., Ph.D. - MAASTRICHT UNIVERSITY - Senior Post-doc

Dr. Sebastien Foulquier

Pharm.D., Ph.D.

MAASTRICHT UNIVERSITY

Senior Post-doc

MAASTRICHT | Netherlands

ORCID logohttps://orcid.org/0000-0002-2523-0748

Dr. Sebastien Foulquier, Pharm.D., Ph.D. - MAASTRICHT UNIVERSITY - Senior Post-doc

Dr. Sebastien Foulquier

Pharm.D., Ph.D.

Introduction


Sébastien Foulquier studied pharmaceutical sciences at the Faculty of Pharmacy of Nancy, France from 2002 until 2008 where he specialized in R&D. He joined the Cardiovascular division of the Servier Research Institute in Suresnes, near Paris for his senior internship before graduating with a Pharm.D. thesis that was awarded by the Faculty as “Best experimental Pharm.D. thesis”. He pursued his studies with a Master in Physiopathology and pharmacology of the cardiovascular system in Lyon, France and a PhD in Cardiovascular Pharmacology at Nancy University, France. During his PhD, he studied the impact of hypertension and the renin angiotensin system on the structure and function of the cerebral circulation in vivo. He completed his PhD in 3 years and got awarded with a prize for the best PhD thesis from the Faculty of Pharmacy. He joined Maastricht University in July 2012 as post-doctoral researcher. Affiliated at both Cardiovascular (CARIM) and Neuroscience (MHeNS) Institutes in Maastricht, he is now leading several research projects on Vascular Cognitive Impairment with a focus on the contribution of vascular risk factors (especially Hypertension) to Blood Brain Barrier dysfunction, Microglial activation and Cognitive dysfunction. He has obtained research grants from the European Society of Hypertension and Servier in 2015, from the Young Talent Program of the Dutch Heart Foundation-CVON “Heart-Brain Connection” in 2016, from the European Foundation for the Study of Diabetes EFSD-Boehringer Ingelheim in 2018 together with Prof C. Schalkwijk and Prof R. van Oostenbrugge. He is furthermore involved in two ongoing European projects: H2020-MSCA-ITN-EJD INTRICARE as PI, and in H2020-PHC SVD@target as participant. He is currently working as Senior Post-doctoral researcher, teaching within the Faculty of Health, Medicine and Life Sciences, pursuing his inter-disciplinary research on Vascular Cognitive Impairment and co-supervising 4 PhD students.

Primary Affiliation: MAASTRICHT UNIVERSITY - MAASTRICHT , Netherlands

Research Interests:

Education

Oct 2008 - Jan 2012
Université de Lorraine Faculté de Pharmacie
Ph.D. Cardiovascular pharmacology
Sep 2007 - Jun 2008
Université Claude Bernard Lyon 1
M.Sc. Cardiovascular pathology and pharmacology
Sep 2002 - Jun 2008
Université de Lorraine Faculté de Pharmacie
Pharm.D. R&D

Experience

Jul 2012 - Jul 2012
Maastricht University
Post-doc
CARIM
Oct 2008 - Oct 2008
Université de Lorraine Faculté de Pharmacie
PhD student
EA 3452 Cardiovascular pharmacology

Publications

12Publications

324Reads

4Profile Views

29PubMed Central Citations

Brain perivascular macrophages: connecting inflammation to autonomic activity in hypertension.

Hypertens Res 2020 Feb 19;43(2):148-150. Epub 2019 Nov 19.

Department of Pharmacology-Toxicology, Maastricht University, Maastricht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41440-019-0359-7DOI Listing
February 2020
2.658 Impact Factor

Transiently proliferating perivascular microglia harbor M1 type and precede cerebrovascular changes in a chronic hypertension model.

J Neuroinflammation 2019 Apr 10;16(1):79. Epub 2019 Apr 10.

Department of Neurology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho Kamigyo-ku, Kyoto, 602-8566, Japan.

View Article

Download full-text PDF

Source
https://jneuroinflammation.biomedcentral.com/articles/10.118
Publisher Site
http://dx.doi.org/10.1186/s12974-019-1467-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456949PMC
April 2019
30 Reads
5.408 Impact Factor

Hypertension-induced cognitive impairment: insights from prolonged angiotensin II infusion in mice.

Hypertens Res 2018 Oct 17;41(10):817-827. Epub 2018 Aug 17.

CARIM, School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41440-018-0090-9
Publisher Site
http://dx.doi.org/10.1038/s41440-018-0090-9DOI Listing
October 2018
49 Reads
2.660 Impact Factor

Combined Angiotensin Receptor Modulation in the Management of Cardio-Metabolic Disorders.

Drugs 2016 Jan;76(1):1-12

CARIM-School for Cardiovascular Diseases, Maastricht University, PO Box 616, 6200 MD, Maastricht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-015-0509-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700059PMC
January 2016
37 Reads
2 Citations
4.343 Impact Factor

Impact of short-term treatment with telmisartan on cerebral arterial remodeling in SHR.

PLoS One 2014 15;9(10):e110766. Epub 2014 Oct 15.

Université de Lorraine, CITHÉFOR "Drug targets, formulation and preclinical assessment," EA3452, Faculté de Pharmacie, Nancy, France.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0110766PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4198293PMC
December 2015
21 Reads
1 Citation
3.234 Impact Factor

Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis.

J Hypertens 2014 Jun;32(6):1334-41

aCARIM, School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands bKlinik für Innere Medizin III, University Clinic of the Saarland, Homburg/Saar cDepartment of Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Germany dCardiovascular Medicine, John Radcliffe Hospital, Oxford, UK ePopulation Health Research Institute, McMaster University, Hamilton, Ontario, Canada fBoehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/HJH.0000000000000154DOI Listing
June 2014
37 Reads
2 Citations
4.720 Impact Factor

AT(2) receptor and tissue injury: therapeutic implications.

Curr Hypertens Rep 2014 Feb;16(2):416

CARIM - School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11906-013-0416-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906548PMC
February 2014
44 Reads
11 Citations
3.440 Impact Factor

Differential effects of short-term treatment with two AT1 receptor blockers on diameter of pial arterioles in SHR.

PLoS One 2012 5;7(9):e42469. Epub 2012 Sep 5.

EA3452 CITHEFOR Drug Targets, Formulation and Preclinical Assessment, Faculté de Pharmacie, Université de Lorraine, Nancy, France.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0042469PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3434186PMC
February 2013
35 Reads
1 Citation
3.234 Impact Factor

Perspective: A tale of two receptors.

Nature 2013 Jan;493(7434):S9

CARIM-School for Cardiovascular Diseases, Maastricht University, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/493S9aDOI Listing
January 2013
24 Reads
3 Citations
42.351 Impact Factor

Impact of the AT(2) receptor agonist C21 on blood pressure and beyond.

Curr Hypertens Rep 2012 Oct;14(5):403-9

Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11906-012-0291-6DOI Listing
October 2012
10 Reads
7 Citations
3.440 Impact Factor

High salt intake abolishes AT(2)-mediated vasodilation of pial arterioles in rats.

J Hypertens 2011 Jul;29(7):1392-9

EA3452 'Drug targets, formulation and preclinical drug evaluation', Faculty of Pharmacy, Nancy-University, Nancy, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/HJH.0b013e328347050eDOI Listing
July 2011
15 Reads
2 Citations
4.720 Impact Factor

Top co-authors

Thomas Unger
Thomas Unger

Charité-Universitätsmedizin Berlin

6
Isabelle Lartaud
Isabelle Lartaud

Université de Lorraine

4
Ulrike Muscha Steckelings
Ulrike Muscha Steckelings

Institute of Pharmacology

3
Pawel Namsolleck
Pawel Namsolleck

Charité-Universitätsmedizin Berlin

3
Chiara Recarti
Chiara Recarti

Maastricht University

2
Caroline Perrin-Sarrado
Caroline Perrin-Sarrado

Université de Lorraine

2
Christine Capdeville-Atkinson
2
Jeffrey Atkinson
Jeffrey Atkinson

Brock University

2